Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment.
Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment.
复制标题
DOI：
10.1186/s40001-023-01330-0
复制
发表时间：
2023-10-04
影响因子：
4.2
通讯作者：
Wang, Min
中科院分区：
文献类型：
--
作者：
Fang, Yenan;Shen, Bingyan;Dai, Qin;Xie, Qiqi;Wu, Wencan;Wang, Min
眼眶炎性假瘤(OIP)是一种良性的、非特异性的炎症性疾病，通常发生在中年人，通常是单侧的，但也可以双侧发生。其临床表现具有很大的异质性，并根据浸润性病变的部位和程度而有所不同，包括眼眶疼痛、肿胀、复视、眼球突出、眼球运动受限和视力下降。临床表现、影像特征及病理检查常需评估以确定诊断。目前，OIP的发病机制尚无系统研究，可能与免疫或感染有关。一线治疗是糖皮质激素。放射治疗、免疫抑制剂和生物制剂可考虑用于治疗抵抗、激素依赖或不耐受的患者。在这篇综述中，我们旨在总结和关注对OIP的新见解，包括新的诊断标准、发病机制以及新药和治疗策略的发现。特别是，我们突出了文献，发现T细胞介导的免疫反应与OIP的发病密切相关。进一步探讨T细胞在免疫过程中的作用机制和信号通路，有助于确定其治疗靶点，开展靶向治疗，治疗难治性OIP，减少传统治疗的副作用。
Orbital inflammatory pseudotumor (OIP) is a benign, non-specific inflammatory disorder that commonly occurs in middle-aged adults and is usually unilateral but can occur bilaterally. Its clinical manifestations have tremendous clinical heterogeneity and vary according to the site of infiltration and the degree of lesions, including orbital pain, swelling, diplopia, proptosis, restricted eye movement, and decreased visual acuity. Clinical features, Image characteristics and pathological examinations often need to be evaluated to confirm the diagnosis. Currently, there is no systematic research on the pathogenesis of OIP, which may be related to immunity or infection. The first-line treatment is glucocorticoids. Radiotherapy, immunosuppressants, and biologics can be considered for treatment-resistant, hormone-dependent, or intolerant patients. In this review, we aim to summarize and focus on new insights into OIP, including new diagnostic criteria, pathogenesis, and discoveries in new drugs and treatment strategies. In particular, we highlight the literature and find that T cell-mediated immune responses are closely related to the pathogenesis of OIP. Further exploration of the mechanism and signaling pathway of T cells in the immune process will help to identify their therapeutic targets and carry out targeted therapy to treat refractory OIP and reduce the side effects of traditional treatments.
登录
查看更多内容
影响因子：
13.7
作者：
Ben Artsi, Elad;Mckelvie, Penelope A.;McNab, Alan A.
通讯作者：
McNab, Alan A.
DOI：
10.1016/s1529-1839(05)70300-6
发表时间：
2005-04-01
期刊：
Optometry (St. Louis, Mo.)
影响因子：
--
作者：
Culligan, Brian
通讯作者：
Culligan, Brian
影响因子：
0.6
作者：
Chaudhry IA;Shamsi FA;Arat YO;Riley FC
通讯作者：
Riley FC
影响因子：
3.3
作者：
Cruz, Antonio Augusto V.;Alves-Ferreira, Eliza V. C.;Cruz, Angela Kaysel
通讯作者：
Cruz, Angela Kaysel
影响因子：
5.5
作者：
Bashant KR;Vassallo A;Herold C;Berner R;Menschner L;Subburayalu J;Kaplan MJ;Summers C;Guck J;Chilvers ER;Toepfner N
通讯作者：
Toepfner N